New Analysis Reveals Icosapent - GuruFocus.com
GuruFocus Article or News written by GuruFocusNews and the topic is about:
Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GuruFocus Article or News written by GuruFocusNews and the topic is about:
-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) - read this article along with other careers information, tips and advice on BioSpace
Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. This upgrade is part of ...
Investegate announcements from AstraZeneca PLC, Tremelimumab US Priority Review for Imfinzi combo